www.fdanews.com/articles/86137-mgi-pharma-publishes-data-on-dacogen-trial
MGI PHARMA PUBLISHES DATA ON DACOGEN TRIAL
April 18, 2006
MGI Pharma has published data from a randomized, controlled Phase III trial of Dacogen for injection, a treatment for myelodysplastic syndromes, in the journal Cancer.
The company conducted the randomized, controlled trial of Dacogen versus supportive care in 170 patients with myelodysplastic syndromes meeting French-American-British subtypes and IPSS intermediate-1, intermediate-2, and high-risk prognostic scores.